Fresenius SE upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded Fresenius SE to Overweight from Neutral with a price target of EUR 40.10, up from EUR 37.60. The stock’s risk/reward looks “more interesting” with the full exit from the key drags FMC and Vamed, coupled with the inflexion at Kabi and continued delivery at Helios, the analyst tells investors in a research note.